On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Penguin Solutions, Inc. (NASDAQ:PENG) “sells at a low multiple, and I don’t mind a low-multiple tech stock because they tend not to get hurt as much as the others.”

On the earnings front, Penguin Solutions reported better-than-expected fourth-quarter results on Oct. 6 and issued FY27 EPS guidance above estimates.

Penguin Solutions reported $566.69 million in fourth-quarter revenue, beating analyst estimates of $516.12 million, according to Benzinga Pro. Total revenue rose 68% year over year. The AI factory platform company posted fourth-quarter adjusted earnings of $1 per share, beating estimates of 78 cents per share.

When asked about Revolution Medicines, Inc. (NASDAQ:RVMD), he said, “I think you have to let it run.”

On Oct. 20, Revolution Medicines announced that it has begun treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer. The trial tests the company’s investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation.

Price Action

• Penguin Solutions shares jumped 7.4% to settle at $58.99 on Tuesday.
• Revolution Medicines shares rose 1.3% to close at $186.22 during the session.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.